CN108473563B - 改进的tnf结合剂 - Google Patents

改进的tnf结合剂 Download PDF

Info

Publication number
CN108473563B
CN108473563B CN201680076588.6A CN201680076588A CN108473563B CN 108473563 B CN108473563 B CN 108473563B CN 201680076588 A CN201680076588 A CN 201680076588A CN 108473563 B CN108473563 B CN 108473563B
Authority
CN
China
Prior art keywords
isvd
seq
amino acid
tnf
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680076588.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473563A (zh
Inventor
玛丽-安格·比斯
约阿希姆·布克内奥
彼得·卡斯特尔
吉诺·范黑克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of CN108473563A publication Critical patent/CN108473563A/zh
Application granted granted Critical
Publication of CN108473563B publication Critical patent/CN108473563B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Insulating Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CN201680076588.6A 2015-11-12 2016-11-14 改进的tnf结合剂 Active CN108473563B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12
US62/254,375 2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en) 2015-11-12 2016-11-14 Improved tnf binders

Publications (2)

Publication Number Publication Date
CN108473563A CN108473563A (zh) 2018-08-31
CN108473563B true CN108473563B (zh) 2022-06-14

Family

ID=57348648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680076588.6A Active CN108473563B (zh) 2015-11-12 2016-11-14 改进的tnf结合剂

Country Status (36)

Country Link
US (2) US10544211B2 (enExample)
EP (2) EP3191511B1 (enExample)
JP (2) JP6962915B2 (enExample)
KR (2) KR20240029115A (enExample)
CN (1) CN108473563B (enExample)
AU (2) AU2016352943B2 (enExample)
CA (2) CA3005085C (enExample)
CL (1) CL2018001291A1 (enExample)
CO (1) CO2018005915A2 (enExample)
CR (1) CR20180311A (enExample)
CY (1) CY1120303T1 (enExample)
DK (1) DK3191511T3 (enExample)
DO (1) DOP2018000122A (enExample)
EC (1) ECSP18042569A (enExample)
ES (1) ES2662418T3 (enExample)
GT (1) GT201800095A (enExample)
HK (1) HK1248716A1 (enExample)
HR (1) HRP20171949T1 (enExample)
HU (1) HUE035805T2 (enExample)
IL (2) IL310373A (enExample)
LT (1) LT3191511T (enExample)
MA (1) MA41653A (enExample)
MD (1) MD3191511T2 (enExample)
ME (1) ME02954B (enExample)
MX (1) MX385207B (enExample)
NO (1) NO2768984T3 (enExample)
PE (1) PE20181317A1 (enExample)
PH (1) PH12018501025A1 (enExample)
PL (1) PL3191511T3 (enExample)
PT (1) PT3191511T (enExample)
RS (1) RS56676B1 (enExample)
SG (1) SG11201803975SA (enExample)
SI (1) SI3191511T1 (enExample)
SM (1) SMT201700590T1 (enExample)
TN (1) TN2018000159A1 (enExample)
WO (1) WO2017081320A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
AU2020397210A1 (en) * 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L
EP4069733A1 (en) * 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
CN116615453A (zh) * 2020-12-18 2023-08-18 埃博灵克斯股份有限公司 包含靶向IL-6和TNF-α的免疫球蛋白单可变结构域的多肽
JP2024543134A (ja) * 2021-11-29 2024-11-19 江蘇恒瑞医薬股▲ふん▼有限公司 修飾されたタンパク質又はポリペプチド
AU2023373192A1 (en) * 2022-11-04 2025-04-17 St. Jude Children's Research Hospital, Inc. Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
WO2026132417A1 (en) * 2024-12-19 2026-06-25 Ablynx Nv Enteral delivery of immunoglobulin single variable domains

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248087A (zh) * 2005-05-18 2008-08-20 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
WO2013024059A2 (en) * 2011-08-17 2013-02-21 Glaxo Group Limited Modified proteins and peptides
CN104203975A (zh) * 2011-06-23 2014-12-10 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
CN106661100A (zh) * 2014-05-16 2017-05-10 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2011256169A (ja) * 2002-11-08 2011-12-22 Ablynx Nv 治療用ポリペプチドの投与法およびそのためのポリペプチド
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP5049973B2 (ja) 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌
CA2632866A1 (en) 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
JP2009517069A (ja) 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
EP3414268A1 (en) * 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248087A (zh) * 2005-05-18 2008-08-20 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
CN104203975A (zh) * 2011-06-23 2014-12-10 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
WO2013024059A2 (en) * 2011-08-17 2013-02-21 Glaxo Group Limited Modified proteins and peptides
CN106661100A (zh) * 2014-05-16 2017-05-10 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.;J. C. Cordy,et al.;《Clinical & Experimental Immunology》;20130911;第182卷(第2期);139-148 *
抗TNF-α骆驼化人源sdAbs库的构建及筛选;王俪蒙,陈伟强,张素娟,王尚,王静,王涛,乔海晅,赵小玲.;《军事医学》;20130525;第37卷(第5期);339-344 *

Also Published As

Publication number Publication date
CL2018001291A1 (es) 2018-09-14
IL259269A (en) 2018-07-31
IL310373A (en) 2024-03-01
NO2768984T3 (enExample) 2018-06-09
RS56676B1 (sr) 2018-03-30
MD3191511T2 (ro) 2018-03-31
RU2018120524A3 (enExample) 2020-09-24
IL259269B1 (en) 2024-03-01
JP7357038B2 (ja) 2023-10-05
MX2018005992A (es) 2019-01-31
US10544211B2 (en) 2020-01-28
CA3234178A1 (en) 2017-05-18
DOP2018000122A (es) 2018-09-30
BR112018009714A2 (en) 2018-11-21
KR102641194B1 (ko) 2024-02-26
BR112018009714A8 (pt) 2019-02-26
PH12018501025A1 (en) 2019-01-28
WO2017081320A1 (en) 2017-05-18
ECSP18042569A (es) 2018-07-31
SMT201700590T1 (it) 2018-01-11
KR20240029115A (ko) 2024-03-05
EP3266798A3 (en) 2018-03-28
KR20180083382A (ko) 2018-07-20
CN108473563A (zh) 2018-08-31
IL259269B2 (en) 2024-07-01
HUE035805T2 (en) 2018-05-28
LT3191511T (lt) 2018-01-10
TN2018000159A1 (en) 2019-10-04
EP3266798A2 (en) 2018-01-10
MX385207B (es) 2025-03-04
SI3191511T1 (en) 2018-01-31
HK1248716A1 (en) 2018-10-19
AU2023200113A1 (en) 2023-02-16
AU2016352943A1 (en) 2018-06-07
EP3191511A1 (en) 2017-07-19
PT3191511T (pt) 2017-11-30
JP2022020666A (ja) 2022-02-01
PE20181317A1 (es) 2018-08-14
ME02954B (me) 2018-07-20
HRP20171949T1 (hr) 2018-01-26
US20170190769A1 (en) 2017-07-06
EP3191511B1 (en) 2017-09-20
JP6962915B2 (ja) 2021-11-10
CR20180311A (es) 2018-10-18
DK3191511T3 (en) 2018-01-08
GT201800095A (es) 2019-08-15
RU2018120524A (ru) 2019-12-13
CO2018005915A2 (es) 2018-06-20
PL3191511T3 (pl) 2018-03-30
CA3005085C (en) 2024-09-10
CA3005085A1 (en) 2017-05-18
SG11201803975SA (en) 2018-06-28
US9745372B2 (en) 2017-08-29
AU2016352943B2 (en) 2022-10-20
JP2019506839A (ja) 2019-03-14
ES2662418T3 (es) 2018-04-06
MA41653A (fr) 2018-01-09
CY1120303T1 (el) 2019-07-10
US20170267752A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
JP7357038B2 (ja) 改善されたｔｎｆ結合因子
US12428497B2 (en) Multispecific antibody constructs
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US20230242677A1 (en) Multi-specific antibodies
RU2774823C2 (ru) Усовершенствованные агенты, связывающие tnf
HK1238660B (en) Improved tnf binders
HK1238660A1 (en) Improved tnf binders
BR112018009714B1 (pt) Ligantes de tnf aperfeiçoados
KR20250099289A (ko) 개선된 면역글로불린 가변 도메인

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant